by Danny Sullivan – Longevity.Technology –
Stately Bio founder explains how combining machine learning and imaging is redefining what it’s possible to measure in biology.
The recent launch of Stately Bio has highlighted a key bottleneck in regenerative medicine: the inability to monitor living cells in real time without destroying them. After three years in stealth mode, the Palo Alto-based startup emerged this month with $12 million in seed funding and a platform that combines machine learning and advanced imaging to address this longstanding challenge.
